Akebia Therapeutics (NASDAQ:AKBA) Sentiment Change Report at 1.35

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Corporate Logo

Akebia Therapeutics’s Sentiment

“Big money sentiment for Akebia Therapeutics (NASDAQ:AKBA) in 2018 Q2 decreased to 1.35, according to SEC.gov filings. That’s down -0.55, from 2018Q1’s 1.9. 69 investment professionals started new or increased stock positions, while 51 trimmed and sold positions in Akebia Therapeutics so the sentiment is negative. These funds own 39.91 million shares, that’s up from 39.14 million shares in 2018Q1. Funds holding Akebia Therapeutics in top 10 changed to 2 from 1 for an increase of 1. 22 Investors Sold All; 29 Reduced Holdings; 47 increased holdings while 22 investment professionals bought holdings.

Most Akebia Therapeutics Investors

Dafna Capital Management Llc owns 610,738 shares in Akebia Therapeutics as of 2018 Q2. As of 2018 Q2, 494,361 shares of Akebia Therapeutics are owned by Clearbridge Llc. Nantahala Capital Management Llc reported 4.52 million shares. Opus Point Partners Management Llc revealed 50,004 shares position in Akebia Therapeutics. The Connecticut-based fund P.A.W. Capital Corp holds 100,000 shares or 1.01% of their portfolio.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology.The firm is valued at $486.71 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients.Currently it has negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

The last price was $8.53.It’s downtrending since December 8, 2017 and is 55.19% up. AKBA underperformed by 70.81% the S&P500.

On March, 11 WallStreet awaited Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s earnings report, RTT reports. Analysts have expectation on stock’s EPS of $-0.80. That’s down 420.00 % from last year’s $0.25 EPS. Wall Street sees 73.91 % negative EPS growth as of March, 11.

Prudential Finance holds 0% of its capital in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 18,770 shs. Laurion Capital Mngmt Limited Partnership has invested 0.04% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Daiwa Securities Grp holds 261 shs or 0% of its capital. Schwab Charles Invest Mngmt invested in 382,512 shs or 0% of the stock. Jefferies Gru Ltd Liability Corporation reported 33,500 shs. Clearbridge owns 494,361 shs or 1.89% of their US capital. Envestnet Asset holds 0% or 2,025 shs. Foundry Prtnrs Ltd Liability Co invested in 77,310 shs. Tiaa Cref Limited Liability Corp holds 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA) or 466,487 shs. Opus Point Prtn Mngmt Ltd Liability Com holds 50,004 shs or 1.08% of its capital. Stanley owns 341,489 shs. Citadel Advsr Limited Liability holds 0% or 620,336 shs. Macquarie Group Ltd reported 27,000 shs. Wellington Mgmt Grp Llp stated it has 565,857 shs. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Management Corp has invested 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA).

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Coverage

A total of 2 analysts rate Akebia Therapeutics (NASDAQ:AKBA) as follows: 1 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 50% are bullish. (NASDAQ:AKBA) has 2 ratings reports on 8 Dec 2018 according to StockzIntelligence. On Friday, September 7 the stock has “Equal-Weight” rating by Morgan Stanley.

For more Akebia Therapeutics, Inc. (NASDAQ:AKBA) news posted briefly go to: Benzinga.com, Gurufocus.com, Nasdaq.com, Seekingalpha.com or Businesswire.com. The titles are as follows: “85 Biggest Movers From Friday – Benzinga” posted on November 12, 2018, “David Abrams Buys 3 Stocks in 3rd Quarter – GuruFocus.com” on November 14, 2018, “Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates – Nasdaq” with a publish date: November 08, 2018, “Tricida readies IPO – Seeking Alpha” and the last “Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors – Business Wire” with publication date: August 28, 2018.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.